Paper Details

  1. Home
  2. Paper Details

The comparison of the effects of DL-308, a potential new neuroleptic agent, and thioridazine on some psychological and physiological functions in healthy volunteers.

Author: BradshawC M, GasznerP, SzabadiE

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

DL-308, a new drug, and thioridazine both displayed sedative properties, with DL-308 being more potent. DL-308 also showed sympathomimetic properties, while both drugs had effects consistent with alpha-adrenolytic and possibly anticholinergic actions. DL-308 had a faster onset and shorter duration of action than thioridazine and had less impact on autonomic functions.
Paper Details　
Original Abstract of the Article :
Eight healthy male volunteers participated in four experimental sessions in which they ingested either DL-308 (10 mg), DL-308 (20 mg), thioridazine (50 mg) or placebo. Drugs were allocated to subjects and sessions in a double-blind fashion according to a balanced cross-over design. Both DL-308 and t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF00432129

データ提供：米国国立医学図書館（NLM）

DL-308: A New Neuroleptic Agent

The world of neuroleptic agents is a complex and fascinating one. This research explores the potential of a new neuroleptic agent, DL-308, and compares its effects to those of thioridazine, an established neuroleptic. The study involved healthy volunteers, meticulously monitoring the impact of these agents on various psychological and physiological functions. Through a controlled, double-blind experiment, researchers meticulously analyzed the effects of DL-308 and thioridazine, revealing their unique properties and potential applications.

Unveiling the Properties of DL-308

The study revealed that DL-308 possesses powerful sedative properties, comparable to thioridazine. Additionally, DL-308 displayed a unique sympathomimetic property, potentially affecting the sympathetic nervous system. Interestingly, the study also noted that DL-308 had a faster time-course of action than thioridazine, reaching peak effects within 1-3 hours and dissipating within 5 hours.

Navigating the Desert of Neuroleptic Effects

This research provides valuable insights into the potential of DL-308 as a new neuroleptic agent. The study's findings suggest that DL-308 may have potential for treating various conditions, particularly those related to anxiety and agitation. However, further research is needed to fully understand its long-term effects and potential risks.

Dr.Camel's Conclusion

This study offers a glimpse into the potential of DL-308 as a new neuroleptic agent. Its fast-acting properties and unique characteristics make it a promising candidate for further investigation. However, as with any new drug, we must proceed with caution, carefully analyzing its effects and potential risks before embracing it as a standard treatment.

Date :
  1. Date Completed 1981-01-16
  2. Date Revised 2019-07-26
Further Info :

Pubmed ID

6107945

DOI: Digital Object Identifier

10.1007/BF00432129

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.